Zemplar



Indications and Reactions:

Role Indications Reactions
Primary
Product Used For Unknown Indication 34.6%
Drug Use For Unknown Indication 27.4%
Hyperparathyroidism Secondary 8.1%
Renal Failure Chronic 6.2%
Renal Failure 4.5%
Hypertension 4.3%
Hyperparathyroidism 4.0%
Anaemia 2.2%
Hyperphosphataemia 1.3%
Diabetes Mellitus 1.2%
Vitamin Supplementation 1.2%
Coronary Artery Disease 1.0%
Prophylaxis 0.6%
Pain 0.6%
Cardiac Disorder 0.6%
Anticoagulant Therapy 0.5%
Renal Disorder 0.5%
Hyperlipidaemia 0.4%
Blood Cholesterol Increased 0.4%
Atrial Fibrillation 0.4%
Death 54.1%
Myocardial Infarction 4.6%
Cardiac Disorder 4.1%
Sepsis 3.4%
Vomiting 3.2%
Unevaluable Event 3.0%
Adverse Event 2.7%
Cardiac Failure 2.7%
Renal Transplant 2.4%
Pyrexia 2.3%
Cerebrovascular Accident 2.0%
Pneumonia 1.9%
Cardiac Arrest 1.8%
Fatigue 1.8%
Pruritus 1.8%
Renal Failure Chronic 1.7%
Diarrhoea 1.7%
Renal Failure 1.7%
Shunt Occlusion 1.6%
Cardiovascular Disorder 1.5%
Secondary
Product Used For Unknown Indication 55.0%
Drug Use For Unknown Indication 17.5%
Hyperparathyroidism Secondary 6.8%
Hypertension 3.4%
Renal Failure Chronic 2.9%
Hyperparathyroidism 2.3%
Dialysis 1.5%
Diabetes Mellitus 1.1%
Anaemia 1.1%
Hyperphosphataemia 1.1%
Arthralgia 0.9%
Coronary Artery Disease 0.8%
Arteriosclerosis Obliterans 0.8%
Localised Infection 0.8%
Procedural Hypotension 0.8%
Hyperlipidaemia 0.8%
Renal Failure 0.8%
Renal Disorder 0.6%
Muscle Spasms 0.5%
Nephrogenic Anaemia 0.5%
Arteriosclerosis Obliterans 16.3%
Tooth Disorder 9.6%
Hypercalcaemia 6.4%
Vomiting 6.1%
Pericardial Effusion 5.8%
Shunt Occlusion 4.7%
Cardiac Failure 4.4%
Myocardial Infarction 4.4%
Pneumonia 4.4%
Shunt Thrombosis 4.4%
Death 4.1%
Unevaluable Event 3.8%
Renal Failure 3.5%
Sinus Tachycardia 3.5%
Weight Decreased 3.5%
Dysgeusia 3.2%
Skin Ulcer 3.2%
Syncope 3.2%
Peripheral Arterial Occlusive Disease 2.9%
Tonsillitis 2.9%
Concomitant
Drug Use For Unknown Indication 39.6%
Product Used For Unknown Indication 23.0%
Nuclear Magnetic Resonance Imaging 8.8%
Angiogram 3.2%
Peritoneal Dialysis 3.0%
Pain 2.4%
Dialysis 2.2%
Renal Failure Chronic 2.1%
Hyperparathyroidism Secondary 2.0%
Hypertension 2.0%
Nuclear Magnetic Resonance Imaging Brain 2.0%
Anaemia 1.9%
Haemodialysis 1.3%
Thrombosis Prophylaxis 1.1%
Nuclear Magnetic Resonance Imaging Abdominal 1.0%
Diabetes Mellitus 1.0%
Prophylaxis 1.0%
Imaging Procedure 0.9%
Hyperphosphataemia 0.9%
Multiple Myeloma 0.7%
Vomiting 24.1%
Skin Tightness 11.6%
Therapeutic Response Decreased 7.9%
Skin Induration 5.2%
Death 5.0%
Peritonitis Bacterial 5.0%
Nephrogenic Systemic Fibrosis 4.8%
Respiratory Failure 3.9%
Nausea 3.7%
Thirst 3.3%
Thrombocytopenia 3.1%
Tremor 3.1%
Oedema Peripheral 2.7%
Weight Decreased 2.7%
Skin Ulcer 2.5%
Hypotension 2.3%
Renal Failure 2.3%
Sepsis 2.3%
Wheezing 2.3%
Aplasia Pure Red Cell 2.1%
Interacting
Product Used For Unknown Indication 73.3%
Blood Parathyroid Hormone Increased 6.7%
Metastases To Lung 6.7%
Renal Cell Carcinoma 6.7%
Renal Failure Chronic 6.7%
Drug Interaction 50.0%
Skin Lesion 50.0%